BIOLASE (NASDAQ: BIOL) has recently received a number of price target changes and ratings updates:

• 12/3/2022 – BIOLASE is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
• 11/25/2022 – BIOLASE is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
• 11/17/2022 – BIOLASE is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
• 11/16/2022 – BIOLASE had its price target lowered by analysts at Ascendiant Capital Markets to $14.00.
• 11/16/2022 – BIOLASE had its price target lowered by analysts at Benchmark Co. to $7.00.
• 11/11/2022 – BIOLASE had its price target lowered by analysts at Maxim Group from $10.00 to $5.00.
• 11/9/2022 – BIOLASE is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
• 11/1/2022 – BIOLASE is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
• 10/24/2022 – BIOLASE is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
• 10/16/2022 – BIOLASE is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
• 10/8/2022 – BIOLASE is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.

BIOLASE Stock Down 4.8 %

Shares of NASDAQ:BIOL opened at $0.78 on Wednesday. The firm's 50 day moving average price is $1.80 and its 200 day moving average price is $3.39. The stock has a market cap of $5.59 million, a price-to-earnings ratio of -0.22 and a beta of 1.34. BIOLASE, Inc. has a fifty-two week low of $0.76 and a fifty-two week high of $13.83. The company has a quick ratio of 1.27, a current ratio of 2.46 and a debt-to-equity ratio of 0.92.

Institutional Trading of BIOLASE

Several hedge funds have recently added to or reduced their stakes in BIOL. Commonwealth Equity Services LLC raised its holdings in BIOLASE by 117.8% in the first quarter. Commonwealth Equity Services LLC now owns 101,046 shares of the medical technology company's stock valued at $35,000 after acquiring an additional 54,650 shares in the last quarter. Essex Investment Management Co. LLC increased its stake in BIOLASE by 2.5% in the first quarter. Essex Investment Management Co. LLC now owns 1,621,992 shares of the medical technology company's stock valued at $573,000 after purchasing an additional 39,281 shares during the last quarter. State Street Corp increased its stake in BIOLASE by 4.5% in the first quarter. State Street Corp now owns 436,076 shares of the medical technology company's stock valued at $154,000 after purchasing an additional 18,682 shares during the last quarter. Capital Wealth Alliance LLC purchased a new position in BIOLASE in the second quarter valued at approximately $51,000. Finally, Citadel Advisors LLC purchased a new position in BIOLASE in the second quarter valued at approximately $118,000. Institutional investors and hedge funds own 21.21% of the company's stock.

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications.

Read More

• Get a free copy of the StockNews.com research report on BIOLASE (BIOL)
• Ulta Issues A Beautiful FY Outlook, But Is the Stock A Buy Now?
• Should The Bancorp Make Your Small-Cap Watchlist for 2023?
• 3 Consumer Cyclical Stocks With Good Momentum
• Could Pinduoduo Be the Best Chinese Stock to Own?
• 3 Big Box Retail Bets for the Holidays

Receive News & Ratings for BIOLASE Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE Inc and related companies with MarketBeat.com's FREE daily email newsletter.